6-K - GH Research PLC | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

GH Research PLC announced the peer-reviewed publication of Phase 2b trial results for GH001 (mebufotenin) in treatment-resistant depression in JAMA Psychiatry, confirming MADRS reduction of -15.5 points vs placebo on Day 8 (P<0.0001) and 57.5% Day 8 remission rate. A new post-hoc analysis shows efficacy independent of prior lifetime antidepressant failures, with Day 8 remission rates of 53.9%-63.6% across subgroups.

Key Takeaways

1Phase 2b primary endpoint met: MADRS reduction -15.5 points vs placebo on Day 8 (P<0.0001)

2Day 8 remission rate 57.5% GH001 vs 0% placebo

3JAMA Psychiatry publication DOI: 10.1001/jamapsychiatry.2026.0096 includes full results and 6-month OLE data

4Post-hoc analysis: Day 8 remission 53.9%-63.6% for 2 to ≥5 prior failures (r=-0.13; P=0.44)

5Month 6 remission 61.5%-85.7% across subgroups

6Advancing GH001 to global pivotal trials

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (3)

6-K

99.1

EXHIBIT 99.1

99.2

EXHIBIT 99.2